MCRN 004 – The LAURENTIANS Trial
Daratumumab (Darzalex®) is the first monoclonal antibody for the treatment of myeloma to be approved by Health Canada. Although daratumumab was approved by Health Canada on April 17, 2017, it is not yet covered by any of the provincial drug plans. For many patients in need, a clinical trial is one of the ways to access this treatment. LAURENTIANS will not only provide access to daratumumab for eligible patients across the country, but it will also answer the question of how to optimize the use of expensive drugs using a cost-effective approach.
Led by Dr Michael Sebag at the McGill University Health Centre in Montreal, this open-label trial is planned to recruit a total of 120 patients across Canada into two study arms. One group will receive daratumumab, cyclophosphamide, dexamethasone and pomalidomide (Pomalyst®). The other group will receive the same treatment regimen, however pomalidomide will only be added when the participant’s disease progresses. Stay tuned for more details.
Participating sites for the LAURENTIANS Trial*
- BCCA Fraser Valley Centre; Surrey, BC
- Cross Cancer Institute; Edmonton, AB
- Tom Baker Cancer Centre; Calgary, AB
- Saskatoon Cancer Centre; Saskatoon, SK
- CancerCare Manitoba; Winnipeg, MB
- Princess Margret Cancer Centre; Toronto, ON
- Juravinski Cancer Centre; Hamilton, ON
- Ottawa General Hospital; Ottawa, ON
- Saint John Regional Hospital; Saint John, NB
- Queen Elizabeth II Health Sciences Centre; Halifax, NS
*Please note that this list is subject to change and site activation dates may vary.